Serum amyloid A protein: A potential biomarker correlated with clinical stage of lung cancer

Biomedical and Environmental Sciences

Volumn 20, Issue 1, 2007, Pages 33-40

  Liu, Dan Hui ^a   Wang, Xiao Min ^a   Zhang, Li Juan ^a   Dai, Song Wei ^a   Liu, Li Yun ^a   Liu, Ji Fu ^b   Wu, Shan Shan ^b   Yang, Shuan Ying ^c   Fu, Sam ^d   Xiao, Xue Yuan ^a   He, Da Cheng ^a  

^a BEIJING NORMAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d CIPHERGEN BIOSYSTEMS INC   (United States)

Author keywords

Biomarker; Lung cancer; On chip identification; Serum amyloid A; Surface enhanced laser desorption ionization

Indexed keywords

PEPTIDE; SERUM AMYLOID A; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; FEMALE; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PROTEIN MICROARRAY; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDES; PROTEIN ARRAY ANALYSIS; SERUM AMYLOID A PROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 34147220127     PISSN: 08953988     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Le L L, Chi K, Tyldesley S, et al. (2005). Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem 51, 695-707.
2. Malik G, Ward M D, Gupta S K, et al. (2005). Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. Clin Cancer Res 11, 1073-1085.
3. Shick A W, Pil P S, Mi B S, et al. (2005). Identification of hemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer. Cancer Sci 96(3), 197-201.
4. Yu Y, Chen S, Wang L S, et al. (2005). Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization- based decision tree classification. Oncology 68(1), 79-86.
5. Traub F, Feist H, Kreipe H H, et al. (2005). SELDI-MS-based expression profiling of ductal invasive and lobular invasive human breast carcinomas. Pathol Res Pract 201(12), 763-770.
6. Chen Y D, Zheng S, Yu J K, et al. (2004). Artificial neural networks analysis of surface-enhanced laser desorption/ionization mass spectra of serum protein pattern distinguishes colorectal cancer from healthy population. Clin Cancer Res 10, 8380-8385.
7. Laronga C, Becker S, Watson P, et al. (2003). SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers 19(4-5), 229-238.
8. Adam B L, Qu Y, Davis J W, et al. (2002). Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62, 3609-3614.
9. Petricoin E F III, Ardekani A M, Hitt B A, et al. (2002). Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359, 572-577.
10. Celis J E, Gromov P, Cabezon T, et al. (2004). Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery. Mol Cell Proteomics 3, 327-344.
11. Block T M, Comunale M A, Lowman M, et al. (2005). Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci 102, 779-784.
12. Lee I N, Chen C H, Sheu J C, et al. (2005). Identification of human hepatocellular carcinoma-related biomarkers by two-dimensional difference gel electrophoresis and mass spectrometry. J Proteome Res 4(6), 2062-2069.
13. Wu W, Tang X, Hu W, et al. (2002). Identification and validation of metastasis-associated proteins in head and neck cancer cell lines by two-dimension electrophoresis and mass spectrometry. Clin Exp Metastasis 19, 319-326.
14. Chen G, Gharib T G, Wang H, et al. (2003). Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci 100, 12537-12542.
15. Kulpa J, Wojcik E, Reinfuss M, et al. (2002). Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA21-1, and neuro-specific enolase in squamous cell lung cancer patients. Clin Chem 48, 1931-1937.
16. Zhong L, Peng X J, Hidalgo G E, et al. (2004). Identification of circulating antibodies to tumor-associated proteins for combined use as markers of non-small cell lung cancer. Proteomics 4, 1216-1225.
17. Spira A, Ettinger D S (2004). Multidisciplinary management of lung cancer. N Engl J Med 350, 379-382.
18. Stieber P, Aronsson A C, Bialk P, et al. (1999). Tumor markers in lung cancer: EGTM recommendations. Anticancer Res 19, 2817-2819.
19. Tolson, J Bogumil, R Brunst E, et al. (2004). Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84(7), 845-856.
20. Yokoi K, Shih L C, Kobayashi R, et al. (2005). Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer. Int J Oncol 27(5), 1361 -1369.
21. Khan N, Cromer C J, Campa M, et al. (2004). Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of non-small cell lung carcinoma. Cancer 101(2), 379-384.
22. Howard B A, Wang M Z, Campa M J, et al. (2003). Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. Proteomics 3(9), 1720-1724.
23. Gao W M, Kuick R, Orchekowski R P, et al. (2005). Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis. BMC Cancer 5, 110.
24. Biran H, Fridman N, Neumann L, et al. (1986). Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 39, 794-797.
25. Yang S Y, Xiao X Y, Zhang W G, et al. (2005). Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC Cancer 5, 83.
26. Xiao X Y, Liu D H, Tang Y, et al. (2004). Development of proteomic patterns for detecting lung cancer. Dis Marker 19(1), 33-39.
27. Xiao X Y, Zhao X D, Liu J K, et al. (2004). Discovery of laryngeal carcinoma by serum proteomic pattern analysis. Sci Chin 47(3), 219-223.
28. Fournier I, Chaurand P, Bolbach G, et al. (2000). Sequencing of a branched peptide using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Mass Spectrom 35, 1425-1433.
29. Mountain C F (1997). Revisions in the international system for staging lung cancer. Chest 111, 1710-1717.
30. Valle R P, Chavany C, Zhukov T A, et al (2003). New approaches for biomarker discovery in lung cancer. Expert Rev Mol Diagn 3,55-67.
31. Zhang L Q, Yu W J, He T, et al. (2002). Contribution of human α-defensin 1,2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 298, 995-1000.
32. Cho W, Yip T, Yip C, et al. (2004). Identificaiton of serum amyloid A protein as a potential useful biomarkers to monitor relapse of nasopharyngeal cancer by serum proteomic profiling. Clin Cancer Res 10, 43-42.
33. Malle E, De Beer F C (1996). Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 26(6), 427-435.
34. Yip T, Chan J, Cho W, et al. (2005). Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid A protein as a biomarker potentially useful in monitoring the extent of pneumonia. Clin Chem 51, 47-55.
35. Kokubun M, Imafuku Y, Okada M, et al. (2005). Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio. Clin Chim Acta 360(1-2), 97-102.
36. Weiinstein P S, Ksinner M, Sipe J D, et al. (1984). Acute phase proteins of tumors markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 19, 193-208.
37. Zheng G, Patolsky F, Cui Y, et al. (2005). Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat Biotechnol 23( 10), 1294-1301.